Description
MT2 10mg (Melanotan II) Research Compound
MT2 10mg from Blacksite Performance is a Melanotan II research compound supplied for laboratory, analytical, and educational research applications.
MT2 (Melanotan II) is a synthetic melanocortin peptide studied in laboratory settings for its interactions with melanocortin receptors and associated cellular signaling pathways. MT2 research includes investigation of receptor activity, pigmentation-related pathways, melanocortin signaling, and other biochemical mechanisms.
MT2 10mg Product Details
- Compound: Melanotan II (MT2)
- Strength: 10mg per vial
- Product: MT2 10mg
- Format: Lyophilized research material
- Container: Research vial
- Intended Use: Laboratory and analytical research only
MT2 Research Applications
MT2 10mg research material may be utilized in controlled laboratory investigations involving the melanocortin system and related biochemical pathways.
- Melanocortin receptor research
- Melanocortin signaling pathways
- Pigmentation-related pathway research
- Receptor-binding studies
- Cellular signaling research
- Biochemical and analytical studies
Quality & Transparency
Blacksite Performance is committed to accurate product representation and research-focused labeling. MT2 10mg product specifications are presented according to available supplier and analytical documentation.
When analytical documentation is available for an applicable product and batch, researchers should review the corresponding documentation through the BSP Lab Results section.
Storage
Store MT2 10mg research material according to the conditions stated on the product label and available supporting documentation. Protect research material from excessive heat, moisture, and direct light where applicable.
FOR RESEARCH USE ONLY.
NOT FOR HUMAN CONSUMPTION.
MT2 10mg is sold exclusively for laboratory, analytical, educational, or research purposes. This product is not intended to diagnose, treat, cure, prevent, or mitigate any disease or medical condition.






Reviews
There are no reviews yet.